黏膜相关淋巴组织淋巴瘤合并干燥综合征1例并文献复习
Mucosal-Associated Lymphoid Tissue Lymphoma with Sjogren’s Syndrome: A Case Report and Literature Review
摘要: 目的:报道黏膜相关淋巴组织淋巴瘤(mucosa associated lymphoid tissue, MALT)并干燥综合征(Primary Sjögren’s Syndrome, SS)的临床特点与诊治重点,分析其预后。方法:回顾1例MALT并SS患者的临床资料并复习相关文献。结果:本例报道的MALT并pSS患者以肺部结节为首发表现,无明显伴随症状,经多次肺组织穿刺活检的病理结果不能排除淋巴瘤可能,结合免疫组化结果确诊为MALT合并SS,在疾病进展过程中可根据胸部CT检查结果发现肺内结节的增长趋势,经过治疗后随访,患者现病情稳定。结论:MALT并pSS患者较少,发病隐匿,初期临床表现可不典型,根据临床表现及影像学检查易漏诊,临床医师在疾病诊断过程中需加强对MALT并pSS的认识,及时给予治疗。
Abstract: Objective: To report the clinical features, diagnosis and treatment of mucosa associated lymphoid tissue (MALT) and Primary Sjögren’s Syndrome (pSS), and analyze its prognosis. Methods: The clinical data of a case of MALT complicated with SS were reviewed and the related literature was reviewed. Results: The patients with MALT and pSS reported in this case presented with pulmonary nodules as the first symptom, and there were no obvious accompanying symptoms. The pathological results of lung biopsy for many times could not rule out the possibility of lymphoma. Combined with immunohistochemical results, MALT with SS was diagnosed. In the process of disease progress, the growth trend of pulmonary nodules could be found according to the results of chest CT examination. After treatment and follow-up, the patient’s condition was stable. Conclusion: There are few patients with MALT complicated with pSS, and the initial clinical manifestations are atypical. According to the clinical manifestations and imaging examination, it is easy to miss the diagnosis. Clinicians should strengthen their understanding of MALT complicated with pSS in the process of disease diagnosis.
文章引用:尹高慧, 王吉波, 孙琳茜. 黏膜相关淋巴组织淋巴瘤合并干燥综合征1例并文献复习[J]. 临床医学进展, 2024, 14(4): 2943-2949. https://doi.org/10.12677/acm.2024.1441375

参考文献

[1] Apaydın, H., Bicer, C., Yurt, E., et al. (2022) AB0552 Elevated Kynurenine Levels in Patients with Primary Sjögren’s Syndrome. Annals of the Rheumatic Diseases, 81, 1401-1403. [Google Scholar] [CrossRef
[2] Foguem, C., Seror, R. and Gosset, M. (2022) Chemosensory Dysfunction in Primary Sjögren’s Syndrome: A Topical Review. Clinical Rheumatology, 42, 1-14. [Google Scholar] [CrossRef] [PubMed]
[3] Isaacson, P.G. and Wright, D. (1983) Malignant Lymphoma of Mucosa-Associated Lymphoid Tissue—A Distinctive Type of B-Cell Lymphoma. Cancer, 52, 1410-1416. [Google Scholar] [CrossRef
[4] Jo, V. and Fletcher, C. (2013) WHO Classification of Soft Tissue Tumours. Pathology, 46, 95-104.
[5] Vallabhapurapu, S. and Karin, M. (2009) Regulation and Function of NF-κB Transcription Factors in the Immune System. Annual Review of Immunology, 27, 693-733. [Google Scholar] [CrossRef] [PubMed]
[6] Zhu, H., Zheng, J., Zhou, Y., et al. (2021) Knockdown of RSAD2 Attenuates B Cell Hyperactivity in Patients with Primary Sjögren’s Syndrome (PSS) via Suppressing NF-κB Signaling Pathway. Molecular and Cellular Biochemistry, 476, 2029-2037. [Google Scholar] [CrossRef] [PubMed]
[7] Beinke, S. and Ley, S.C. (2004) Functions of NF-KappaB1 and NF-KappaB2 in Immune Cell Biology. Biochemical Journal, 382, 393-409. [Google Scholar] [CrossRef
[8] Nordmark, G., Wang, C., Vasaitis, L., et al. (2013) Association of Genes in the NF‐κB Pathway with Antibody‐Positive Primary Sjögren’s Syndrome. Scandinavian Journal of Immunology, 78, 447-454. [Google Scholar] [CrossRef] [PubMed]
[9] Nocturne, G., Boudaoud, S., Miceli, C., et al. (2013) Germline and Somatic Genetic Variations of TNFAIP3 in Lymphoma Complicating Primary Sjogren’s Syndrome. Blood, 122, 4068-4076. [Google Scholar] [CrossRef] [PubMed]
[10] Nocturne, G., Tarn, J., Boudaoud, S., et al. (2015) Germline Variation of TNFAIP3 in Primary Sjögren’s Syndrome-Associated Lymphoma: Table 1. Annals of the Rheumatic Diseases, 75, 780-783. [Google Scholar] [CrossRef] [PubMed]
[11] Nocturne, G., Virone, A., Ng, W.-F., et al. (2015) Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren’s Syndrome. Arthritis & Rheumatology (Hoboken, N.J.), 68, 977-985. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, W., Lin, J., Cao, H., et al. (2015) Local and Systemic IKKε and NF-κB Signaling Associated with Sjögren’s Syndrome Immunopathogenesis. Journal of Immunology Research, 2015, Article ID: 534648. [Google Scholar] [CrossRef] [PubMed]
[13] Tilioua, S., Mezioug, D., Amir-Tidadini, Z.C., et al. (2020) Potential Role of NF-κB Pathway in the Immuno-Inflammatory Responses during Human Cystic Echinococcosis. Acta Tropica, 203, Article ID: 105306. [Google Scholar] [CrossRef] [PubMed]
[14] Wei, H., Wang, B., Miyagi, M., et al. (2013) PRMT5 Dimethylates R30 of the P65 Subunit to Activate NF-κB. Proceedings of the National Academy of Sciences of the United States of America, 110, 13516-13521. [Google Scholar] [CrossRef] [PubMed]
[15] Hoshida, Y., Xu, J.X., Fujita, S., et al. (2007) Lymphoproliferative Disorders in Rheumatoid Arthritis: Clinicopathological Analysis of 76 Cases in Relation to Methotrexate Medication. The Journal of Rheumatology, 34, 322-331.
[16] Okabe, M., Inagaki, H., Ohshima, K., et al. (2003) API2-MALT1 Fusion Defines a Distinctive Clinicopathologic Subtype in Pulmonary Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. The American Journal of Pathology, 162, 1113-1122. [Google Scholar] [CrossRef
[17] Remstein, E.D., Kurtin, P.J., Einerson, R.R., et al. (2004) Primary Pulmonary MALT Lymphomas Show Frequent and Heterogeneous Cytogenetic Abnormalities, Including Aneuploidy and Translocations Involving API2 and MALT1 and IGH and MALT1. Leukemia, 18, 156-160. [Google Scholar] [CrossRef] [PubMed]
[18] Streubel, B., Simonitsch-Klupp, I., Müllauer, L., et al. (2004) Variable Frequencies of MALT Lymphoma-Associated Genetic Aberrations in MALT Lymphomas of Different Sites. Leukemia, 18, 1722-1726. [Google Scholar] [CrossRef] [PubMed]
[19] Reichenberger, F., Wyser, C., Gonon, M., et al. (2001) Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma in a Patient with Common Variable Immunodeficiency Syndrome. Respiration, 68, 109-112. [Google Scholar] [CrossRef] [PubMed]
[20] Borie, R., Wislez, M., Thabut, G., et al. (2009) Clinical Characteristics and Prognostic Factors of Pulmonary MALT Lymphoma. European Respiratory Journal, 34, 1408-1416. [Google Scholar] [CrossRef] [PubMed]
[21] Alu, A., Lei, H., Han, X., et al. (2022) BTK Inhibitors in the Treatment of Hematological Malignancies and Inflammatory Diseases: Mechanisms and Clinical Studies. Journal of Hematology & Oncology, 15, Article No. 138. [Google Scholar] [CrossRef] [PubMed]
[22] Burger, J.A. (2019) Bruton Tyrosine Kinase Inhibitors: Present and Future. The Cancer Journal, 25, 386-393. [Google Scholar] [CrossRef
[23] Fares, A., Uribe, C., Rehman, T., et al. (2024) Bruton’s Tyrosine Kinase Inhibitors: Recent Updates. International Journal of Molecular Sciences, 25, Article No. 2208. [Google Scholar] [CrossRef] [PubMed]
[24] Mano, H. (1999) Tec Family of Protein-Tyrosine Kinases: An Overview of Their Structure and Function. Cytokine & Growth Factor Reviews, 10, 267-280. [Google Scholar] [CrossRef